Answers are grounded in this paper and cite their sources.
Background: Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC.Methods: The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Conversions were performed using 2020 purchasing-power-parity ($US PPP).Results: Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) were finally included (13 European, 6 USA and 1 Canadian). The assessed populations included early- (n=4), and intermediate-advanced-stages patients (n=15). Included studies were evaluated from a payer perspective (n=20) and included both payer and social perspective (n=2). TARE was compared with transarterial chemoembolization (TACE) (n=9) or sorafenib (n=11). Life-years gained for TARE ranged from 1.3 to 3.1 vs. TACE and from 1.1 to 2.53 for TARE vs. sorafenib. TARE was associated with lower treatment cost in ten studies. TARE cost varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1,311 PPP/month (BCLC-A) to 71,890 PPP/horizon time 5 years (BCLC-C). The incremental cost-utility ratio for TARE vs TACE resulted in a $PPP 17,397/Quality-adjusted-Life-Years (QALY) (n=1) and for TARE vs. sorafenib ranged from dominant (more effectiveness and lower cost) to 3,363 PPP/QALY.Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.
No takes yet. Share an insight, caveat, or question.
Casáns et al. (2022) studied this question.